Plandai Biotechnology Inc (OTCMKTS:PLPL) reported that the amended deal with USN will help it to increase its Phytofare® sales to USN and all its related contract manufacturers. For the record, USN was established back in 2000 and since then it has stayed a known health and nutrition supplement brand in the industry. The group has managed to enhance its customer base and moved to rapid expansion through strong commitment towards product innovation. It has reputed chain of raw material suppliers and excellent customer support across the world.
In last trading session, the stock price of Plandai jumped over 7% to close the trading session at $0.150. The gains came at a share volume of 33,300 compared to average monthly share volume of 75,942.
Flex Pharma Inc (NASDAQ:FLKS) Elects Rob Perez To Its Board
Flex Pharma Inc (NASDAQ:FLKS) a biotechnology firm developing innovative treatments for exercise-related nocturnal leg cramps and muscle cramps, and spasms linked with neuromuscular conditions, reported that Mr. Robert J. Perez, who was the former CEO of Cubist Pharmaceuticals Inc (NASDAQ:CBST) has joined company’s Board.
Flex Pharma stated that Mr. Perez joined Cubist Pharmaceuticals in 2003, as Senior VP, Sales and Marketing and headed the launch of Cubicin®. He served as COO and Executive Vice President for the company from year 2007 to 2012 and COO and President 2012 to 2014. Prior to his association with Cubist, he served as VP of Biogen Inc (NASDAQ:BIIB)’s CNS Business segment from 2001 to 2003, where he looked after commercial operations of neurology business unit. Mr. Perez serves on the Board of Cidara Therapeutics Inc (NASDAQ:CDTX) and AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).
Following the news, the stock of Flex Pharma jumped more than 9% on Tuesday to close the day at $12.46. CDTX and AMAG posted gains of over 6% and 2%, respectively.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: